News

Public · Published

REGN Stock Hits 2-Year Highs Pre-Market: CFO Says Regeneron Is Positioned To Deliver One Of 'Strongest Years Ever' After Q3 Earnings Beat

Regeneron reported third-quarter revenue up 36% to $5.12 billion and adjusted earnings per share up 70% to $20.07, both beating estimates. The chief financial officer credited strong drug sales and higher Sanofi collaboration revenue.

Published:

Updated:

What happened

Regeneron reported third-quarter revenue up 36% to $5.12 billion and adjusted earnings per share up 70% to $20.07, both beating estimates. The chief financial officer credited strong drug sales and higher Sanofi collaboration revenue.

Confirmed

Global impact / market context

Higher revenue and profit per sale show Regeneron is selling more drugs and collecting more from its Sanofi partnership. That combination can fund research and lift investor confidence, which helps explain the premarket jump and why the stock may reach its highest level since October 2024.

Analyst inference

The results suggest demand for Regeneron's eye treatments remains solid, even as patients move from original Eylea to Eylea HD, which means a newer, higher-dose version. Investors appear to be rewarding that shift and the Sanofi revenue step-up, rather than treating the older drug's decline as a problem.

Analyst inference

What to watch

  1. Watch whether the premarket gain holds after the opening bell, since the article says shares would hit their highest level since October 2024 if those levels persist. Confirmed
  2. Regeneron could face pressure to show that Eylea HD sales keep replacing original Eylea sales, so watch whether the switch continues at a similar pace in coming quarters. Proposed
  3. Higher Sanofi collaboration revenue may not repeat at the same size, so watch whether future results rely more on drug sales to sustain revenue and profit growth. Analyst inference

Evidence